Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monovalent rLukS-PV
- Development stage
- Phase 2
- Lead developer
- Vaxart
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Monovalent rLukS-PV is an investigational recombinant protein subunit vaccine component designed to prevent infections caused by *Staphylococcus aureus*. It consists of a detoxified version (toxoid) of the LukS-PV protein, which is one of the two subunits (LukS-PV and LukF-PV) that form the Panton-Valentine Leukocidin (PVL) toxin. PVL is a pore-forming cytotoxin produced by many strains of *S. aureus*, particularly community-associated methicillin-resistant *S. aureus* (CA-MRSA), and is associated with skin and soft tissue infections as well as necrotizing pneumonia. By inducing antibodies against LukS-PV, the vaccine aims to neutralize the toxin's ability to lyse host immune cells, such as neutrophils. It has been evaluated in Phase 1/2 clinical trials both as a monovalent formulation and in combination with rAT (recombinant alpha-toxin) by the Henry M. Jackson Foundation and Integrated BioTherapeutics.
- Other names
- recombinant LukS-PVStaphylococcus aureus LukS-PV toxoid
02
Targets
LukS-PV (Panton-Valentine leukocidin S component)
Beyond the preview
Go deeper on monovalent rLukS-PV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monovalent rLukS-PV.